{
  "id": 5466866,
  "title": "Insight Innovation: The Risky Bet on the First Cancer Vaccine",
  "url": "https://urgent.news/2026/09/04/insight-innovation-die-riskante-wette-auf-den-ersten-impfstoff-gegen",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-04T02:00:00.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/technik/forschung-innovation/hautkrebs-die-riskante-wette-auf-den-ersten-impfstoff-gegen-krebs/100248932.html"
  },
  "original_language": "de",
  "account": "Moderna has announced positive test results for an innovative skin cancer vaccine developed in partnership with Merck & Co. The vaccine, which uses mRNA technology, showed strong results in a large study, marking a potential breakthrough in cancer treatment. The medication could be on the market as early as 2027, with analysts predicting billions in sales. Moderna's CEO, Stéphane Bancel, is leading the company's efforts in this area, following their successful COVID-19 vaccine development.",
  "summary": "Skin cancer could soon be fought using the same principle that was used to tame the coronavirus. Moderna and Merck are reporting success with an mRNA vaccine. However, there are hurdles.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}